Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Packaging: Package as customer's requirements
Transportation: Ocean,Land,Air,Express,Others
Supply Ability: in stock
Port: jinan,qingdao ,beijing
Payment Type: L/C,T/T,D/P
Incoterm: FOB,CFR,CIF
Introduction:Avatrombopag is the world's first FDA-approved oral thrombopoietin receptor agonist (TPO-RA) for CLD-related thrombocytopenia. Adult patients with chronic liver disease-related thrombocytopenia undergoing diagnostic procedures or surgery
Thrombocytopenia is one of the common complications in patients with chronic liver disease, and up to 78% of patients with cirrhosis are accompanied by varying degrees of thrombocytopenia. When patients with chronic liver disease have thrombocytopenia, the risk of procedure-related bleeding is significantly increased, which in turn leads to a series of clinical invasive tests and treatments that cannot be carried out as usual. Therefore, when surgery or other invasive tests are required, patients with CLD-related thrombocytopenia have a particularly urgent need for a rapid increase in platelet counts in a short period of time. In addition to CLD-related thrombocytopenia, avatrombopag is also deployed in the fields of chemotherapy-induced thrombocytopenia (CIT) and immune thrombocytopenia (ITP). The global phase III clinical trial of thrombocytopenia (CIT) has completed patient enrollment
CAS | 677007-74-8 |
MF | C33H38Cl2N6O7S2 |
MW | 765.72 |
Purity | 99%+ |
Product Categories : API Intermediates > Avatrombopag Maleate Intermediate
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.